Adult Social CareAlzheimer'sCareCare HomesCare ProvidersDementiaHealthcareHomecareNewsNHSNursing HomesSocial Care

Alzheimer’s Association Backs New Trial of GLP-1 Drugs to Reduce Cognitive Decline

The Alzheimer’s Association today announced the launch of the PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy), a first of-its-kind global clinical trial designed to evaluate whether combining a proven multidomain lifestyle intervention with a metabolism-targeting drug, such as a GLP-1 agonist, can further reduce the risk of cognitive decline, mild cognitive impairment (MCI), and dementia in at-risk older adults.

The $100 million effort was announced today for the first time at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London.

Building on the success of the Alzheimer’s Association-led U.S. POINTER, and LatAm FINGERS studies, PROTECT-Cog represents the next phase in advancing research focused on risk reduction/prevention strategies for Alzheimer’s and other diseases that cause dementia.

“PROTECT-Cog builds directly on what we learned from U.S. POINTER and takes the next critical step in prevention science,” said Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead at the Alzheimer’s Association, and principal investigator of the study.

“By testing a combined approach that targets both lifestyle and biology, we have the opportunity to better understand how to meaningfully reduce the risk of cognitive decline before symptoms begin.” “Now is the time to accelerate bold, science-driven strategies to prevent or delay dementia,” said Joanne Pike, DrPH, president and CEO of the Alzheimer’s Association.

“The PROTECT-Cog Study reflects our commitment to leading large-scale, rigorous research that explores and expands urgently needed treatment options, including how combining interventions may deliver even greater benefit for those at highest risk.” A growing body of research demonstrates that modifiable lifestyle factors — including physical activity, nutrition, cardiovascular health, sleep, and social engagement — play a critical role in brain health and dementia risk.

The U.S. POINTER study showed that a highly representative population of at-risk older Americans who followed a structured, multidomain lifestyle intervention experienced significantly greater cognitive benefits compared with those using a self-guided approach.

These improvements were equivalent to approximately one to two years of cognitive advantage, along with additional benefits in reducing frailty and sleep apnea, and improving blood pressure regulation.

 

Nescafe26Blue